Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Jacoby

Showing results (321-330 of 338) with videos related to

Pageof 34
Sort By:
JCI Insight|March 9, 2018
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplantMeagan A Jacoby, Eric J Duncavage, Gue Su Chang, et al.
Cancer Medicine|October 24, 2017
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimenAlaa M Ali, Daniel Weisel, Feng Gao, et al.
Haematologica|March 3, 2022
Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapyFrancesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Blood Advances|June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMMLAndrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
Blood|January 14, 2017
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapyEric J Duncavage, Geoffrey L Uy, Allegra A Petti, et al.
Blood|November 19, 2021
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapyMelissa M Berrien-Elliott, Michelle Becker-Hapak, Amanda F Cashen, et al.
Leukemia|October 15, 2016
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapyG L Uy, E J Duncavage, G S Chang, et al.
Blood Cancer Discovery|June 16, 2022
Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome ProgressionAndrew J Menssen, Ajay Khanna, Christopher A Miller, et al.
Nature Reviews. Microbiology|November 4, 2011
Tackling antibiotic resistanceKaren Bush, Patrice Courvalin, Gautam Dantas, et al.
Pageof 34

Showing results (321-330 of 338) with videos related to

Sort By:
Pageof 34
JCI Insight|March 9, 2018
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplantMeagan A Jacoby, Eric J Duncavage, Gue Su Chang, et al.
Cancer Medicine|October 24, 2017
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimenAlaa M Ali, Daniel Weisel, Feng Gao, et al.
Haematologica|March 3, 2022
Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapyFrancesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Blood Advances|June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMMLAndrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
Blood|January 14, 2017
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapyEric J Duncavage, Geoffrey L Uy, Allegra A Petti, et al.
Blood|November 19, 2021
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapyMelissa M Berrien-Elliott, Michelle Becker-Hapak, Amanda F Cashen, et al.
Leukemia|October 15, 2016
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapyG L Uy, E J Duncavage, G S Chang, et al.
Blood Cancer Discovery|June 16, 2022
Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome ProgressionAndrew J Menssen, Ajay Khanna, Christopher A Miller, et al.
Nature Reviews. Microbiology|November 4, 2011
Tackling antibiotic resistanceKaren Bush, Patrice Courvalin, Gautam Dantas, et al.
Pageof 34